TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03299179

Intervention type: BIOLOGICAL
Intervention: Blood sample
Description: Blood sample after MRI-session: measurement of hematocrit, hemoglobin, estradiol, progesterone, follicle stimulation hormone and luteinizing hormone.

Intervention type: BIOLOGICAL
Intervention: Blood sample
Description: Blood sample after MRI-session: measurement of hematocrit, hemoglobin, estradiol, progesterone, follicle stimulation hormone and luteinizing hormone.

Intervention type: DEVICE
Intervention: Blood pressure measurement
Description: Measuring blood pressure before and after MRI-scan

Intervention type: DEVICE
Intervention: Blood pressure measurement
Description: Measuring blood pressure before and after MRI-scan

Intervention type: DEVICE
Intervention: Body temperature
Description: Measuring body temperature before and after MRI-scan

Intervention type: DEVICE
Intervention: Body temperature
Description: Measuring body temperature before and after MRI-scan

Intervention type: OTHER
Intervention: Questionnaires
Description: Questionnaires at the start of the study on lifestyle. Additionally, a questionnaire before each scan session on the actual state of the volunteer (e.g. mood, caffeine consumption, alcohol, medication, etc.)

Intervention type: OTHER
Intervention: Questionnaires
Description: Questionnaires at the start of the study on lifestyle. Additionally, a questionnaire before each scan session on the actual state of the volunteer (e.g. mood, caffeine consumption, alcohol, medication, etc.)

Intervention type: DIAGNOSTIC_TEST
Intervention: Pregnancy test
Description: Test for pregnancy using a pregnancy dipstick test
Study: NCT03473028

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transabdominal ultrasound guided embryo transfer
Description: 400 female with body mass index more than 30undergo transabdominal ultrasound guided embryo transfer

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transvaginal ultrasound guided embryo transfer
Description: 400 female with body mass index more than 30 undergo transvaginal ultrasound guided embryo transfer
Study: NCT03224962

Intervention type: DEVICE
Intervention: fluorescence camera
Description: drug - diagnostic test
Study: NCT03433066

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Advanced platelet-rich fibrin mixed with biphasic alloplast
Description: mucoperiosteal flaps will be reflected to expose the defects , which will be debrided properly and finally filled with the freshly prepared Advanced platelet-rich fibrin mixed with the biphasic alloplast.
Study: NCT01849081

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: Subjects in the intervention arm will be treated with continuous positive airway pressure (CPAP) device at night.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: LIfestyle
Description: Subjects will undergo 12 weeks of dietary counseling.
Study: NCT02177487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/hydrochlorothiazide
Study: NCT03433066

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biphasic alloplast mixed with saline
Description: mucoperiosteal flap will be reflected to expose and clean the intrabony defect ,then it will be filled with biphasic alloplast mixed with saline.
Study: NCT00467844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTx-024
Description: 1 mg GTx 024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTx-024
Description: 3 mg GTx-024

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study: NCT01593982

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation (rTMS)
Description: 20 daily sessions: each with 25 trains of 10 seconds at 5Hz, with a 20 second inter-train interval, at an intensity of 120% of motor threshold.~Site: Left Dorsolateral Prefrontal Cortex

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation (rTMS)
Description: 20 daily sessions: each with 25 trains of 10 seconds at 5Hz, with a 20 second inter-train interval, at an intensity of 120% of motor threshold.~Site: Left Dorsolateral Prefrontal Cortex
Study: NCT02580162

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FBT for Pediatric Weight Management by Professionals
Description: This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change. This 20 week treatment is adapted from our existing evidence-based interventions and is delivered by PROFESSIONAL interventionists.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FBT for Pediatric Weight Management by Professionals
Description: This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change. This 20 week treatment is adapted from our existing evidence-based interventions and is delivered by PROFESSIONAL interventionists.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FBT for Pediatric Weight Management by Peers
Description: This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change. This 20 week treatment is adapted from our existing evidence-based interventions and is provided by PEER interventionists.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FBT for Pediatric Weight Management by Peers
Description: This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change. This 20 week treatment is adapted from our existing evidence-based interventions and is provided by PEER interventionists.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Interventionists
Description: Parents who receive FBT complete 6 weeks of training and then serve as peer interventionists to a new group of families.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Interventionists
Description: Parents who receive FBT complete 6 weeks of training and then serve as peer interventionists to a new group of families.
Study: NCT00688038

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser Ablation
Description: Laser ablation procedure taking about 1-3 hours, depending on the size and location of the tumor.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Thermal Imaging
Description: MRTI will be used to monitor the temperature within the ablation zone during the laser ablation.
Study: NCT00440323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-649868
Description: SB-649868 tablets will be available with dose strength of 5 and 25 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-649868
Description: SB-649868 tablets will be available with dose strength of 5 and 25 mg.
Study: NCT06308861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single administration Dmg dose Group
Description: Orally, Dmg tablet single administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single administration Emg dose Group
Description: Orally, Emg tablet single administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Single administration Amg dose Group-Placebo
Description: Orally, Placebo Amg tablet, single administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Single administration Bmg dose Group-Placebo
Description: Orally, Placebo Bmg tablet, single administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Single administration Cmg dose Group-Placebo
Description: Orally, Placebo Cmg tablet, single administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Single administration Dmg dose Group-Placebo
Description: Orally, Placebo Dmg tablet, single administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Single administration Emg dose Group-Placebo
Description: Orally, Placebo Emg tablet, single administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple administration Amg dose group
Description: Orally, Amg 1 tablet, once a day for 3 days, multiple administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple administration Bmg dose group
Description: Orally, Bmg 1 tablet, once a day for 3 days, multiple administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple administration Cmg dose group
Description: Orally, Cmg 1 tablet, once a day for 3 days, multiple administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple administration Dmg dose group
Description: Orally, Dmg 1 tablet, once a day for 3 days, multiple administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple administration Emg dose group
Description: Orally, Emg 1 tablet, once a day for 3 days, multiple administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Multiple administration Amg dose group - Placebo
Description: Orally, Placebo Amg 1 tablet, once a day for 3 days, multiple administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Multiple administration Bmg dose group - Placebo
Description: Orally, Placebo Bmg 1 tablet, once a day for 3 days, multiple administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Multiple administration Cmg dose group - Placebo
Description: Orally, Placebo Cmg 1 tablet, once a day for 3 days, multiple administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Multiple administration Dmg dose group - Placebo
Description: Orally, Placebo Dmg 1 tablet, once a day for 3 days, multiple administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Multiple administration Emg dose group - Placebo
Description: Orally, Placebo Emg 1 tablet, once a day for 3 days, multiple administration
Study: NCT02339558

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT00979043

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Weight-loss
Description: The goal of the dietary weight-loss intervention was to produce and maintain a mean weight-loss of 5% initial body weight during the 18-month intervention, using dietary counseling and behavior modification.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Weight-loss
Description: The goal of the dietary weight-loss intervention was to produce and maintain a mean weight-loss of 5% initial body weight during the 18-month intervention, using dietary counseling and behavior modification.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Participants participated in resistance training (15 minutes) and aerobic exercise (30 minutes) 3d/week for 18-months. The first 4-months of the exercise training were facility-based. After 4-months, participants were allowed to transition to a home-based intervention if they chose to.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Participants participated in resistance training (15 minutes) and aerobic exercise (30 minutes) 3d/week for 18-months. The first 4-months of the exercise training were facility-based. After 4-months, participants were allowed to transition to a home-based intervention if they chose to.
Study: NCT01519258

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pressure Support ventilation
Description: Patients will receive usual care during the period of ventilation on the Pressure Support. The same ventilator, the Servoi (maquet, Sweden) will be used.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NAVA
Description: Patients will be ventilated with NAVA for 15 minutes. Back up settings in pressure support mode will be set in case the esophageal catheter is misplaced, and back up settings in pressure control ventilation will be set in case no inspiratory efforts are detected for longer than 15 seconds
Study: NCT01391273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost solution 0.03%
Description: One drop of bimatoprost solution 0.03% applied along each upper eyelid margin once daily in the evening for 4 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bimatoprost vehicle solution
Description: One drop of bimatoprost vehicle solution applied along each upper eyelid margin once daily in the evening for 4 months.
Study: NCT04198363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Vonoprazan Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Amoxicillin Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Amoxicillin Capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: Clarithromycin Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Clarithromycin Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bismuth Potassium citrate
Description: Bismuth Potassium citrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth Potassium citrate
Description: Bismuth Potassium citrate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Esomeprazole Tablets
Study: NCT03642808

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rehabilitation program
Description: Availibility of patients to complete a rehabilitation program during 8 weeks and to come back 4 times for a careful medical examination
Study: NCT03372187

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DIET-MS
Description: Following the completion of testing, all 20 participants will be placed into the DIET-MS group and will follow the prescribed diet plan for 12 weeks. At the end of the 12 weeks, the participants will return to complete follow up testing.
Study: NCT06742541

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable Collamer Lens (ICL) followed by a planned adjunctive LASIK postoperatively
Description: Planned surgery to receive a spherical Implantable Collamer Lens (ICL) followed by a planned adjunctive LASIK postoperatively
Study: NCT02378818

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Force task, preference task, discount task, learning task.
Description: Force task, preference task, discount task, learning task.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Force task, preference task, discount task, learning task.
Description: Force task, preference task, discount task, learning task.
Study: NCT03571282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conbercept
Description: After three monthly injections of conbercept, if no effects was seen in the patients, the patients will receive rescue treatments such as photodynamic therapy (in the macular) or laser photocoagulation (outside the macular).
Study: NCT00440323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-649868
Description: SB-649868 tablets will be available with dose strength of 5 and 25 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-649868
Description: SB-649868 tablets will be available with dose strength of 5 and 25 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: Zolpidem capsules will be available with dose strength of 10 mg.
Study: NCT02233764

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FeZnPM
Description: Iron and zinc biofortified pearl millet will be consumed three times per day, six days per week, for 9 months. Children are anticipated to consume 25-30 grams of the pearl millet at each feeding. The pearl millet will be prepared using a variety of recipes such as porridges, breads, and biscuits.
Study: NCT00369759

Intervention type: OTHER
Intervention: Emergency Dept. Subjects with LRI or Apnea
Description: No intervention; Epidemiological Study

Intervention type: OTHER
Intervention: Emergency Dept. Subjects with LRI or Apnea
Description: No intervention; Epidemiological Study
Study: NCT02233764

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CtrlPM
Description: Conventional pearl millet will be consumed three times per day, six days per week, for 9 months. Children are anticipated to consume 25-30 grams of the pearl millet at each feeding. The pearl millet will be prepared using a variety of recipes such as porridges, breads, and biscuits.
Study: NCT01640106

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3
Description: 800 mg Omega 3 daily (600 mg DHA/200 mg EPA)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a combination of dietary plant-based oils in a paste containing no Omega-3 (EPA or DHA)
Study: NCT03530046

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: High SID fluid
Description: The fluid will be given to the patient at a rate prescribed by the treating physician according to clinical response for a period of 2 hours or up to maximum 30ml/kg fluid is given, whichever is earlier.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Hartmann's solution
Description: The fluid will be given to the patient at a rate prescribed by the treating physician according to clinical response for a period of 2 hours or up to maximum 30ml/kg fluid is given, whichever is earlier.
Study: NCT03760471

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evidenced-based symptom management and coping intervention
Description: The intervention visits will focus on coping and the following symptoms prevalent during CRT: (1) pain and mucositis, (2) nausea, (3) constipation, (4) fatigue, (5) sleep disturbances, (6) xerostomia, (7) thick mucus, and (8) depression
Study: NCT00440323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: Zolpidem capsules will be available with dose strength of 10 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: Zolpidem capsules will be available with dose strength of 10 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: Zolpidem capsules will be available with dose strength of 10 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet matching SB-649868 or Placebo capsule matching Zolpidem will be available.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet matching SB-649868 or Placebo capsule matching Zolpidem will be available.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet matching SB-649868 or Placebo capsule matching Zolpidem will be available.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet matching SB-649868 or Placebo capsule matching Zolpidem will be available.
Study: NCT00358163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTK787/ZK 222584
Description: Taken in tablet form daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given as a 3-hour infusion once every 21 days
Study: NCT00861185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: senicapoc
Description: Loading Dose: 80 mg twice daily x 3 days Maintenance Dose: 40 mg daily for remainder of the treatment period (total 4 weeks)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo looks identical to active study medication and will be dosed according to the same dosing regimen
Study: NCT01919307

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture
Description: The NADA Protocol for auricular acupuncture will be performed by the PI, a certified NADA protocol practitioner, using sterile, single-use, Seiren 0.22mm, one cm disposable detox needles. Both ears will be sterilized with alcohol swabs. There will be no electrical or other stimulation performed. Needles will be placed subcutaneously with one half twirl upon insertion to the following 5 points (in order per ear): Sympathetic, Shen Men, Kidney, Liver, Lung. Needles will remain in place for 40 minutes and will then be removed in the same order as they were inserted. Needles that become dislodged will be replaced per typical NADA protocol.
Study: NCT01209858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel and Microgynon-30
Description: Part A: Microgynon-30 single oral dose on Day 1 Period 1 and Day 35 Period 2; perampanel oral daily dose starting at 4 mg per day Period 2 from Days 1 through 35 and titrated weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel and Microgynon-30
Description: Part B: Perampanel single oral dose of 6 mg on Day 1 Period 1 and Day 21 Period 2; Microgynon-30 orally from Day 1 through Day 21 of Period 2.
Study: NCT01928979

Intervention type: OTHER
Intervention: no drug
Description: Patients who suffered from hemodynamically stable nonvalvular AF or atrial flutter and had a diagnosed LA/ LAA thrombus between January 1st, 2011 and December 31st, 2012
Study: NCT02682810

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DNA PCR HIV diagnostic test
Description: standard of care

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alere Q
Description: POC diagnostic Alere Q qualitative test (along with a DBS drawn for confirmatory DNA PCR)
Study: NCT03570424

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrient support to HIIT
Description: 3 groups of young (aged 18-35 y), healthy, recreationally active, aerobically untrained (VO2max \<50 ml.kg.min-1) males will undertake 3 weeks (9 sessions) of HIIT under different nutrient conditions following \>10h overnight fast: i) Placebo: Fasted artificially flavoured and textured placebo 45 minutes prior to exercise; ii) Whey protein 45 minutes prior to exercise; iii) Whey protein hydrolysate 45 minutes prior to exercise).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrient support to HIIT
Description: 3 groups of young (aged 18-35 y), healthy, recreationally active, aerobically untrained (VO2max \<50 ml.kg.min-1) males will undertake 3 weeks (9 sessions) of HIIT under different nutrient conditions following \>10h overnight fast: i) Placebo: Fasted artificially flavoured and textured placebo 45 minutes prior to exercise; ii) Whey protein 45 minutes prior to exercise; iii) Whey protein hydrolysate 45 minutes prior to exercise).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 groups of young (aged 18-35 y), healthy, recreationally active, aerobically untrained (VO2max \<50 ml.kg.min-1) males will undertake 3 weeks (9 sessions) of HIIT under different nutrient conditions following \>10h overnight fast: i) Fasted artificially flavoured and textured placebo 45 minutes prior to exercise; ii) Fed Whey protein 45 minutes prior to exercise; iii) Fed Whey protein hydrolysate 45 minutes prior to exercise).